Takeda Pharmaceutical Co. has renewed its partnership with the Structural Genomics Consortium (SGC) to fund collective drug research and has invested an additional (CAD) $7.5 million, on top of its initial investment of (CAD) $5 million in 2012. SGC is an open-source collaboration of more than 200 scientists from academia and industry working on human biology and early-stage drug research, the results of which are available to the scientific community. The SGC is based at the University of To...